- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02169609
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Phase II Single Arm Study to Assess Dinutuximab (Ch 14.18) Combined With the Cytokines Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) and IL-2 in Patients With High-risk Neuroblastoma Not Eligible to Other Immunotherapy Trials
Study Overview
Status
Intervention / Treatment
Detailed Description
Assess toxicity and safety of subcutaneous GM-CSF and iv IL-2 in enhancing Dinutuximab-mediated ablation of Bone Marrow (BM) disease in patients with high-risk neuroblastoma who have achieved a Complete Response or Very Good Partial Response of the macroscopic disease in the investigators institution.
Assess response of minimal residual disease (MRD) of the anti-GD2 monoclonal antibody Dinutuximab combined with granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-2 in patients with high-risk neuroblastoma (NB). More precisely, to apply real-time quantitative RT-PCR to test the hypothesis that minimal residual disease content of BM after the first treatments with dinutuximab/GM-CSF has significant prognostic impact on relapse-free survival.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain
- Hospital Sant Joan de Deu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of neuroblastoma as defined by international criteria by histopathology or bone marrow metastases. Patients age must be less than 18 years at the time of initial diagnosis.
Neuroblastoma, as defined by risk-related treatment guidelines and the International Neuroblastoma Staging System, stage 4 with (any age) or without (>18 months) MYCN-amplification, or MYCN-amplified neuroblastoma other than stage 1, or high-risk neuroblastoma defined based on the 3-gene molecular profile developed at our institution (Garcia I, et al. CCR 2012).
- Group 1 patients have neuroblastoma (as defined above) resistant to standard therapy, as evidenced by incomplete response in bone marrow, but no MIBG-avid soft tissue or bone tumor and no progressive disease.
Group 2 patients have no evidence of measurable disease
3 - Patients must have a Lansky or Karnofsky Performance Scale score of > 50% and patients must have a life expectancy of > 2 months.
4- Pre-enrollment tumor survey: Prior to enrollment a determination of residual disease must be Performed (Tumor imaging studies including CT or MRI, MIBG scan, bone marrow aspiration & biopsy, and blood and bone marrow samples). This disease assessment is required for eligibility.
5 - Patients must have adequate organ functions at the time of registration:
- Hematological: Total absolute phagocyte count (APC = neutrophils + monocytes) is at least 1000/microL
- Renal: Adequate Renal Function Defined As: Creatinine clearance or radioisotope GFR > 70 mL/min/1.73 m2 or serum creatinine based on age/gender.
- Hepatic- total bilirubin < 1.5 x normal, and SGPT (ALT) < 5 x normal. Veno-occlusive disease, if present, should be stable or improving.
- Cardiac- shortening fraction of > 30% by echocardiogram, or if shortening fraction abnormal, ejection fraction of > 55% by gated radionuclide study.
- Pulmonary- FEV1 and FVC > 60% of predicted by pulmonary function test. For children who are unable to do PFTs, no evidence of dyspnea at rest, no exercise intolerance.
Central nervous system- Patients with seizure disorder may be enrolled if on anticonvulsants and wellcontrolled. CNS toxicity < Grade 2.
6 - Females of childbearing potential must have a negative pregnancy test. Patients of childbearing potential must agree to use an effective birth control method. Female patients who are lactating must agree to stop breast-feeding.
7 - Signed informed consent indicating awareness of the investigational nature of this program.
Exclusion Criteria:
- - Existing severe major organ dysfunction, i.e., renal., cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity ≥ grade 3.
- - Progressive disease or MIBG-avid soft tissue/bone tumor.
- - Active life-threatening infection.
- - Inability to comply with protocol requirements.
- - Patient is eligible for SIOP HR-NB-01 protocol (= newly diagnosed high-risk neuroblastoma patient in a center where the SIOP protocol is open for enrollment).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dinutuximab. Immunotherapy
Dinutuximab will be administered at 17.5 mg/m2/day for 4 days up to 5 courses. Each dose should be infused IV over approximately 10 hours. Immunotherapy (sargramostim + isotretinoin + interleukin2) Sargramostim will be administered at 250 micrograms/m2/d by subcutaneous (SC) injection daily from Day 0 through 13 (daily with the infusion of Dinutuximab and for 3 days before and 7 days afterward). Isotretinoin (13-cis-retinoic acid, or RA) (160mg/m2/day or 5.33mg/kg/day if < 12kg) PO divided into 2 doses daily x 14 days. Interleukin-2 (IL-2) 3 MIU/m2/day will be given by continuous infusion for 4 days during the first week of each course 2 and 4 given on Days 0 - 3 |
Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses. Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Serious and Non-Serious Adverse Events
Time Frame: Expected, 7 months from treatment initiation. From IC signature, every day during immunotherapy treatment (Cycles 1 to 5), day 1 of cycle 6. From patient consent signature up to 30 days after administration of the last dose of study drug.
|
Type, incidence, severity, timing, seriousness, and relatedness; of reported AEs, physical examinations, and laboratory tests.
Toxicity will be graded and tabulated by the NCI-CTCAE v 4.0.
|
Expected, 7 months from treatment initiation. From IC signature, every day during immunotherapy treatment (Cycles 1 to 5), day 1 of cycle 6. From patient consent signature up to 30 days after administration of the last dose of study drug.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse-free survival
Time Frame: Anticipated, 2 years from study treatment initiation. From IC signature, every 3 months, up to 2 years (anticipated).
|
Rate of BM response for patients with detectable minimal residual disease in the BM after the first treatments with Dinutuximab/GM-CSF and relation with relapse-free survival.
|
Anticipated, 2 years from study treatment initiation. From IC signature, every 3 months, up to 2 years (anticipated).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jaume Mora, MD, Hospital Sant Joan de Deu, Barcelona
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplastic Processes
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Neuroblastoma
- Neoplasm, Residual
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Immunologic Factors
- Dermatologic Agents
- Sargramostim
- Dinutuximab
- Interleukin-2
- Isotretinoin
Other Study ID Numbers
- HSJD-HR-NB-Ch14.18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Effects of Immunotherapy
-
Shanghai Juncell TherapeuticsSir Run Run Shaw HospitalRecruitingAdvanced Solid Tumor | Treatment Side Effects | Effects of Immunotherapy | Tumor Infiltrating LymphocytesChina
-
Philippe BéginThe Hospital for Sick Children; Centre de recherche du Centre hospitalier universitaire... and other collaboratorsRecruitingImmunotherapy | Physiological Effects of Drugs | Food IgE-mediated Allergy | OmalizumabCanada
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingBreast Cancer | Advanced Breast Cancer | Treatment Side Effects | Effects of ImmunotherapyChina
-
Aalborg UniversityCompletedQuality of Life | Hypersensitivity | Asthma | Effects of Immunotherapy | Rhino-Conjunctivitis
-
RadiotherapieCompletedMelanoma | Effects of Immunotherapy | Adverse Effect of Radiation TherapyBelgium
-
Michael von WolffUniversity of BernNot yet recruitingCancer | Fertility Issues | Effects of Immunotherapy | Toxicity Due to Chemotherapy | Toxicity Due to Radiotherapy | Fertility Preservation
-
University Hospital, GrenobleInstitut National de la Santé Et de la Recherche Médicale, France; Etablissement... and other collaboratorsCompletedMelanoma | Effects of Immunotherapy | Tumor VaccinesFrance
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingTreatment Side Effects | Effects of Immunotherapy | Advanced Liver Cancers | Tumor Infiltrating Lymphocyte | Advanced Pancreatic CancersChina
-
Leiden UniversityBristol-Myers SquibbActive, not recruitingEffects of Immunotherapy | Adverse Drug Event | Toxicity, DrugNetherlands
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingTreatment Side Effects | Effects of Immunotherapy | Advanced Melanoma | Tumor Infiltrating LymphocyteChina
Clinical Trials on Dinutuximab. Immunotherapy
-
University Medicine GreifswaldChildren's Cancer Research Institute, AustriaActive, not recruiting
-
Prof. Franca FagioliSuspended
-
Jagiellonian UniversityRecruiting
-
United TherapeuticsTerminatedNeuroblastomaUnited States
-
BeiGeneCompleted
-
Power Life Sciences Inc.Not yet recruiting
-
Leti Pharma GmbHCompletedAllergic Asthma | Allergic RhinoconjunctivitisGermany
-
University Hospital Center of MartiniqueEuropean Georges Pompidou HospitalCompletedImmunotherapyFrance, Martinique
-
Washington University School of MedicineUnknownMelanoma | Skin Cancer | Merkel Cell Carcinoma | Basal Cell Carcinoma | Squamous Cell Carcinoma of the Skin | AutoimmunityUnited States
-
Guangdong Association of Clinical TrialsRecruitingLung Cancer | ImmunotherapyChina